Elevating the Future of Cancer care with Alpha Theranostics (Accelerate.EU)

Project summary

Theranostics is a technique used in personalised medicine, particularly in cancer treatment. The EU-funded Accelerate.EU project aims to revolutionise theranostics through innovative targeted alpha therapies (TATs) using astatine-211. The project will combine diagnostics with the potent cytotoxic effects of alpha particles to enable precise tumour radiation while minimising side effects. It will develop innovative theranostic solutions for hard-to-treat cancers and establish a robust EU manufacturing and treatment infrastructure for astatine-211. The project will also produce educational content to support the deployment of theranostic solutions, strategically develop TATs for pancreatic, breast, and brain cancers, and pioneer 211At-theranostics to empower healthcare providers and improve patient outcomes, creating a lasting impact on cancer care.